Prior therapy with anti-CD20 chimeric antibody (Rituximab) may decrease the risk of acute graft-versus-host disease (GVHD) in patients with non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.

被引：0
|
作者：
Ratanatharathorn, V
Bociek, RG
Pavletic, SZ
Lynch, JC
Ferrara, JLM
Uberti, JP
机构：
[1] Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA
[2] Univ Nebraska, Omaha, NE USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1688
引用
收藏
页码：391A / 391A
页数：1
相关论文
共 50 条
  • [31] INCIDENCE OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN PATIENTS WITH ALLOGENEIC PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER A NON-MYELOABLATIVE CONDITIONING
    Cantu, O. G.
    Gutierrez, H.
    Ruiz, G.
    Mancias, C.
    Martinez, S. A.
    Gonzalez, O.
    Jaime, J. C.
    Gomez, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S314 - S314
  • [32] INCIDENCE OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN PATIENTS WITH ALLOGENEIC PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AFTER A NON-MYELOABLATIVE CONDITIONING
    Cantu, O.
    Gutierrez, H.
    Ruiz, G.
    Lopez, A.
    Mancias, C.
    Martinez, S.
    Gonzalez, O.
    Jaime, J.
    Gomez, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 653 - 653
  • [33] Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in paediatric patients
    Kim, M. S.
    Lee, J. W.
    Kim, H.
    Kang, H. J.
    Park, K. D.
    Shin, H. Y.
    Ahn, H. S.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S112 - S113
  • [34] Chronic graft-versus-host (cGVHD) after non-myeloablative stem cell transplantation (NST) with rituximab-containing conditioning regimens for non-Hodgkin's lymphoma.
    Saliba, Rima M.
    Khouri, Issa F.
    de Lima, Marcos
    Hosing, Chitra
    Okoroji, Grace
    Acholonou, Sandra
    Maadani, Farzaneh
    De Jesus, Jorge
    Hsu, Yvonne
    Champlin, Richard E.
    Couriel, Daniel R.
    BLOOD, 2006, 108 (11) : 421B - 421B
  • [35] Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation
    Mattsson, J
    Uzunel, M
    Brune, M
    Hentschke, P
    Barkholt, L
    Stierner, U
    Aschan, J
    Ringdén, O
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) : 935 - 944
  • [36] IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
    Maloney, DG
    GrilloLopez, AJ
    White, CA
    Bodkin, D
    Schilder, RJ
    Neidhart, JA
    Janakiraman, N
    Foon, KA
    Liles, TM
    Dallaire, BK
    Wey, K
    Royston, I
    Davis, T
    Levy, R
    BLOOD, 1997, 90 (06) : 2188 - 2195
  • [37] Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma
    Shimoni, A
    Hardan, I
    Avigdor, A
    Yeshurun, M
    Raanani, P
    Ben-Bassat, I
    Nagler, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (03) : 457 - 464
  • [38] The interleukin 2 receptor antagonist basiliximab is well tolerated and effective in the therapy of steroid-resistant acute graft-versus-host disease (GvHD) after allogeneic stem cell transplantation.
    Massenkeil, G
    Genvresse, I
    Rackwitz, S
    Reich, G
    Dörken, B
    Arnold, R
    BLOOD, 2001, 98 (11) : 663A - 663A
  • [39] 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma
    Knop, S
    Jakob, A
    Kanz, L
    Hebart, H
    Bares, R
    Dohmen, B
    BLOOD, 2004, 103 (03) : 1175 - 1175
  • [40] Optimal protocol for red marrow dosimetry in high-dose I-131 anti-CD20 monoclonal antibody (rituximab) therapy in patients with non-Hodgkin's lymphoma
    Kim, Kyeong Min
    Park, Ji Ae
    Byun, Byung Hyun
    Kang, Hye Jin
    Choi, Tae Hyun
    Kim, Byung Il
    Cheon, Gi Jeong
    Lim, Sang Moo
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
12345